Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Knowledge about the natural course of brain arteriovenous malformations (AVMs) have increased during the past 20 years, as has the number of AVMs treated, especially larger ones. It is thus timely to again analyze the risk for hemorrhage after Gamma Knife Surgery (GKS).

Objective: To confirm or contradict conclusions drawn 20 years ago regarding factors that affect the risk for post-GKS hemorrhage.

Methods: The outcome after GKS was studied in 5037 AVM patients followed for up to 2 years. The relation between post-treatment hemorrhage rate and a number of patient, AVM, and treatment parameters was analyzed. The results were also compared with the results from our earlier study.

Results: The annual post-treatment hemorrhage rate was 2.4% the first 2 years after GKS. Large size, low treatment dose, and old age were independent risk factors for AVM hemorrhage. After having compensated for the factors above, peripheral AVM location and female sex, at least during their child bearing ages, were factors associated with a lower post-GKS hemorrhage rate.

Conclusion: Large AVMs (>5 cm 3 ) treated with low doses (≤16 Gy) had higher and small AVMs treated with high doses a lower risk for hemorrhage as compared with untreated AVMs. This was detectable within the first 6 months after GKS. No difference in hemorrhage rate could be detected for the other AVMs. Based on our findings, it is advisable to prescribe >16 Gy to larger AVMs, assuming that the risk for radiation-induced complications can be kept at an acceptable level.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632947PMC
http://dx.doi.org/10.1227/neu.0000000000002130DOI Listing

Publication Analysis

Top Keywords

risk hemorrhage
12
avms treated
12
hemorrhage rate
12
gamma knife
8
knife surgery
8
arteriovenous malformations
8
post-treatment hemorrhage
8
avms
7
hemorrhage
7
risk
6

Similar Publications

Background: Relapsed or refractory cases of pediatric acute myeloid leukemia (AML) have poor outcomes despite advancements in chemotherapy and hematopoietic stem cell transplantation (HSCT). While a second HSCT is often a salvage option, its outcomes vary widely, and prognostic factors remain unclear.

Objectives: This study aimed to evaluate outcomes and identify prognostic factors in pediatric patients with AML who underwent multiple HSCTs.

View Article and Find Full Text PDF

Moyamoya syndrome (MMS) is a chronic vasculopathy characterized by progressive stenosis of intracerebral arteries, leading to an increased risk of stroke. Children with Down syndrome (DS) are at an increased risk of co-occurring medical conditions, including MMS and leukemia. We report four patients with the triad of DS, MMS, and acute lymphoblastic leukemia (ALL).

View Article and Find Full Text PDF

Background: Hospital-acquired venous thromboembolism (HA-VTE) is a leading cause of morbidity and mortality among hospitalized adults. Numerous prognostic models have been developed to identify those patients with elevated risk of HA-VTE. None, however, has met the necessary criteria to guide clinical decision-making.

View Article and Find Full Text PDF

While frailty and anemia are prevalent conditions in aging linked to adverse outcomes, their relationship remains understudied in generally healthy older adults. We conducted a post-hoc observational study among all participants of DO-HEALTH, the largest European clinical trial designed to support healthy aging. Our analysis examined whether baseline hemoglobin levels and anemia are associated with being at least pre-frail at baseline and any yearly follow-up time point over three years.

View Article and Find Full Text PDF

Objective: To evaluate the clinical efficacy of tocilizumab, a interleukin-6 (IL-6) receptor blocker, for the treatment of acute necrotizing encephalopathy (ANE).

Methods: PubMed, Cochrane Library, Embase, and Web of Science were searched for systematic review based on PRISMA guidelines. ANE patients treated with and without tocilizumab were included.

View Article and Find Full Text PDF